Publications Office of the EU
Direct contract notice and opinions on haemostasis and platelet counts - Public Procurement procedure view
DisplayCustomHeader
Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates CPV codes deduced from the text of the procedure

- indicates text translated automatically in your browsing language

Direct contract notice and opinions on haemostasis and platelet counts Text automatically translated in your browsing language Automatically translated

  • Today
    03/12/2024
Status
Submission closed
Type of contract
Services
Subject for Renewal
No
Buyer
Fimlab Laboratoriot Oy
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: FI197 Pirkanmaa
Business sector (Main CPV)
85148000 Medical analysis services
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
700,000.00 EUR
Tender reference number
536297
Description

Fimlab Laboratoriot Oy acquires haemostasis and platelet tests and related expert opinions directly from the HUS Diagnostic Centre from 1 January 2025 until further notice. The Tikkurila laboratory of Fimlab Laboratoriot Oy (‘Fimlab’) has conducted approximately 7500 haemostasis studies annually, some of which are package studies of several sub-studies, as well as approximately 650 platelet studies, which are mainly package studies. The main purpose of these studies is the diagnosis and treatment of serious coagulation disorders such as blockage and bleeding tendencies and platelet disorders, as well as the monitoring of platelet-acting medicinal products. Fimlab's operations were transferred to Fimlab from the Finnish Red Cross Blood Service in 2019, but Fimlab has decided to discontinue operations, the maintenance of which in a separate unit located in Tikkurila has become financially burdensome as the number of samples has decreased. As the operations partly overlap with the operations of the HUS Diagnostics Centre, the merger and national centralisation of the operations have been considered justified in order to improve the efficiency of the operations and ensure the preconditions for their development. On 1 January 2025, this analytics will be transferred to the operations of the HUS Diagnostics Centre. After the transfer of the business, HUS is the only operator in Finland that has the necessary special expertise and methodological techniques at its disposal to carry out these rare studies. The wellbeing services counties that own Fimlabi will continue to need to receive studies and statements related to this area. The opinions are always based on the entirety of studies carried out on a case-by-case basis, so commissioning studies from different actors and thus dividing the procurement into smaller sub-assemblies is not acceptable from the point of view of patient diagnostics. As some of the investigations are urgent, obtaining them outside Finland's borders is out of the question. Text automatically translated in your browsing language Automatically translated

Submission Method
Not available
Tenders may be submitted
Not available
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
Not available
Award method
Criterion:
Type: quality
Description: Jatkossa HUS:lla on ainoa laboratorio, joka tuottaa mainittuja tutkimuksia Suomessa.
Weight (percentage, exact): 100
Estimated value
Not available
Final contracted value
700,000.00 EUR
Award of contract
Not available
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.